Q-omics provides the consensus-scored MT2A profile across patient tissues and cancer cell-line models. MT2A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MT2A is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, MT2A protein abundance shows 19,832 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where MT2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT2A survival associations across molecular data types. MT2A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT2A RNA expression–survival associations across cancer types. High MT2A expression shows unfavorable associations in HNSC, KIRC, PAAD, ACC and KICH, but favorable associations in SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MT2A RNA expression.
This table summarizes MT2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MT2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT2A shows lower tumor expression in COAD, LIHC, KICH, BRCA and CHOL and higher tumor expression in HNSC. The COAD box plot shows higher MT2A RNA expression in normal versus tumor tissue (log2 FC = −2.524, t-test p < 0.001).
This table shows molecular features associated with MT2A in patient tissues and cancer cell lines. In patient samples, MT2A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MT2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
